Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry Developments

Top Articles

South Korea

The halt of yet another clinical trial for a biosimilar of Roche's Rituxan (rituximab) highlights the regulatory issues biosimilars are currently experiencing. The delay will benefit... 2013-04-29


Through their involvement in this growing trend, Shionogi, Daiichi Sankyo, Astellas Pharma, Takeda and Eisai can expect to reap huge reputational benefits, as well as access to knowledge... 2013-04-26


We highlight the difficulty Myanmar will face in healthcare financing, given the country's high burden of communicable and non-communicable diseases. The situation is made worse by... 2013-04-25



Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated. BMI's Pharmaceutical Expenditure Model reveals... 2013-04-24


A prescription medicine that treats a 'lifestyle' disease has been launched for the first time as an over-the-counter (OTC) drug in Japan. This is significant given that previous such... 2013-04-18


Frontier markets offer drugmakers, medical device manufacturers and healthcare service providers substantial opportunities. Sales will be low initially and losses are possible for several... 2013-04-16


BMI View: We maintain our positive outlook for the Chinese pharmaceutical market in 2013. Domestic pharmaceutical firms achieved strong revenue growth in 2012, in line with our bullish... 2013-04-09

BMI View: Revenue earning opportunities for pharmaceutical and healthcare companies operating in the Asia Pacific region are largely driven by spending growth in developing countries.... 2013-04-08